The vascular disrupting activity of OXi8006 in endothelial cells and its phosphate prodrug OXi8007 in breast tumor xenografts. Issue 1 (1st December 2015)

• Record Type: Journal Article
• Authors: Strecker, Tracy E.; Odutola, Samuel O.; Lopez, Ramona; Cooper, Morgan S.; Tidmore, Justin K.; Charlton-Sevcik, Amanda K.; Li, Li; MacDonough, Matthew T.; Hadimani, Mallinath B.; Ghatak, Anjan; Liu, Li; Chaplin, David J.; Mason, Ralph P.; Pinney, Kevin G.; Trawick, Mary Lynn
• Is Part Of: Cancer letters. Volume 369:Issue 1(2016)
• Page Start: 229
• Page End: 241
• Publication Date: 2015-12-01
• Subjects: Cancer -- Periodicals; Neoplasms -- Periodicals; Cancer -- Périodiques; Electronic journals; 616.994
• DOI: 10.1016/j.canlet.2015.08.021
• Languages: English
• ISSNs: 0304-3835

Abstract

<abstract abstract-type="author-highlights" id="ab0010"> <title id="st0010">Highlights</title> <sec> <p id="sp0010"> <list id="ulist0010"> <list-item id="u0010"> <label></label> <p id="p0010">The indole-based OXi8006 and its phosphate prodrug OXi8007 are potent vascular disrupting agents.</p> </list-item> <list-item id="u0015"> <label></label> <p id="p0015">Bioluminescence imaging in a breast cancer xenograft mouse model demonstrated that OXi8007 is a potent VDA in vivo.</p> </list-item> <list-item id="u0020"> <label></label> <p id="p0020">VDA properties were confirmed by complementary studies in activated endothelial cells.</p> </list-item> <list-item id="u0025"> <label></label> <p id="p0025">OXi8006 treatment resulted in microtubule disruption, and activation of RhoA kinase.</p> </list-item> <list-item id="u0030"> <label></label> <p id="p0030">Phosphorylation of focal adhesion kinase is essential for the OXi8006 mechanism.</p> </list-item> </list> </p> </sec> </abstract>